Tirzepatide and Breastfeeding: One Study, and Two Opposite Answers Built On It

Two documents, two answers

If you are nursing and were just handed a tirzepatide prescription, there are two authoritative documents you could read, and they will not tell you the same thing.

The first is the label. Mounjaro and Zepbound are the same molecule under two names, and both carry a single-dose clinical lactation study in section 8.2 — real nursing women, measured milk. Neither label tells you to stop. What both say is that the developmental and health benefits of breastfeeding should be considered alongside the mother's clinical need for the drug^1,2. That is a judgment handed back to you and your prescriber.

The second is a consensus guideline published in Obesity Reviews in 2026, written by an international expert group after a systematic review of the field. Its first sentence states that pregnancy concurrent with these medications is contraindicated — and that breastfeeding is too³.

Neither is careless. Understanding why they diverge is the single most useful thing you can take into an appointment, because it tells you which question you are actually deciding.

The number that explains the gap

The expert group screened the literature and pulled 34 articles into its evidence synthesis: 11 randomized trials, nine observational studies, two pharmacovigilance reviews, nine case reports or series, two animal studies and one ex vivo study³.

Of those 34, one addressed lactation. Two addressed contraception. Nearly everything else was about preconception or pregnancy³.

The group set itself 32 research questions and found evidence bearing on 18 of them — 56.3%³. Just one animal study followed offspring beyond birth.

So the two documents are not disagreeing about what the evidence shows. They are disagreeing about what to do when there is almost none. The label reports the one study that exists. The consensus reports the shape of the whole field and defaults to caution. Both are describing the same near-void from opposite ends.

What the one study found

Since the entire lactation evidence base is effectively this, it is worth knowing precisely. Eleven healthy lactating adults received a single 5 mg subcutaneous dose, and their milk was sampled 171 times over a 28-day window¹.

That last row is the honest one, and the label prints it rather than smoothing it over: there was not enough drug in the milk to compute an exposure curve at all.

Now the limits, which are on the same page. There are no available data on effects on the breastfed infant, and none on milk production^1,2. Undetectable in milk is a fact about milk. It is not a fact about the baby who drinks it, and it is not a fact about whether your supply holds.

It was also one dose. You would not be taking one dose, and whether a 10 or 15 mg maintenance dose behaves like a single 5 mg injection is a fair question this study was not built to answer.

The animal data are not blank either. In rats, pups of mothers dosed at 0.25 mg/kg through gestation and lactation had significantly lower mean body weight than controls — postnatal day 7 through 126 in males, through day 56 in females¹. Rat pups are not human infants and the relevance is genuinely unclear. But a piece quoting the reassuring milk numbers and omitting this one would be selling you something.

Nobody has asked women what they would trade

There is one more finding in that review, and it is the one that should be quoted more than it is. Among the 34 articles, the expert group identified no qualitative studies at all³.

Not "few." None. Across everything published on incretin medications and women's reproductive health, no one had sat down with the women making this decision and recorded what they weighed, what they feared, or what they would have traded. The field has measured milk concentrations in eleven women and has never once asked a mother what she wanted to know.

That absence is why so much of the advice you will get sounds confident and lands badly. It was not built with your priorities in it.

Stopping is not the free option

There is a reflex, from clinicians and from mothers, to treat weaning as the zero-risk choice. If in doubt, stop nursing. The evidence on what happens next is worth seeing before you accept that trade.

A 2025 systematic review in the International Breastfeeding Journal pooled 20 studies — nine prospective cohorts, five retrospective surveys, four using qualitative research, one randomized trial and one mixed-methods study — on medication-related breastfeeding discontinuation⁴.

Discontinuation ran from 2% to 18% in general populations, and from 2% to 58% among women with chronic or severe acute conditions⁴. Fourteen of the studies named the medicines involved — 29 of them — and every one except lithium had post-marketing data indicating safety in breastfeeding⁴.

Read that again. Women were stopping over drugs the post-marketing record already supported.

The review also found clinicians pushing in both directions: healthcare professionals were described as encouraging discontinuation in three studies and as reducing it in three others⁴. And the women most likely to stop were not a random slice — risk factors included lower education, cesarean birth, chronic conditions, employment at six months postpartum, less breastfeeding experience and pre-pregnancy smoking⁴. The authors' conclusion is blunt: many of these cessations may be avoidable, and inconsistent advice and systemic barriers likely drive unnecessary ones⁴.

None of that makes tirzepatide safe while nursing. It makes "just stop" a decision with its own costs, taken under the same uncertainty, and it means the answer you get may depend on which clinician you happen to see.

The instruction that catches people out

If you are breastfeeding, there is a decent chance you are also not looking to be pregnant again soon. Here the tirzepatide label carries something specific:

Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time.¹

The remedy is precise. Switch to a non-oral method, or add a barrier method, for four weeks after starting, and for four weeks after every dose increase¹. Not four weeks once — four weeks each time the dose goes up, which on a titration schedule is most of your first several months. Hormonal methods not taken by mouth are unaffected¹. If you are on the mini-pill postpartum, that is the one this hits. Our guide to GLP-1s and birth control works through the alternatives.

The pregnancy section is shorter and unambiguous: tirzepatide may cause fetal harm and should be discontinued when pregnancy is recognized, and there is an exposure registry tracking outcomes, reachable through Eli Lilly at 1-800-LillyRx¹.

What to actually ask

Not "is it safe" — nobody can answer that, and a clinician who does is filling a gap with confidence rather than data. Ask these instead.

"Which of the two positions are you working from?" The label's risk-benefit framing, or the consensus recommendation against it. Both are defensible. Knowing which one you are hearing tells you whether there is a second opinion worth getting.

"What happens to my supply?" This is the practical mechanism that gets the least attention. Appetite suppression means eating less, and eating less can affect supply. It is a nutrition question rather than a drug-safety one, and it needs planning separately.

"What is the cost of waiting?" If the honest answer is a few months, that is a very different decision than if your metabolic risk is active now. The expert group's caution is a default, not a verdict on your case.

"If I stop nursing for this, was that necessary?" Given how often medication-related weaning turns out to be avoidable⁴, it is a fair thing to make someone say out loud.

The bottom line

The single honest summary is that eleven women, one dose and 171 milk samples are the whole of what is known, that a careful expert group looked at that and recommended against nursing, that a careful label looked at the same thing and left the decision with you, and that nobody in the literature has yet asked a mother what she would have chosen.

You are not resolving that disagreement in an appointment. What you can do is know it exists, and stop treating whichever answer you were given first as the settled one.